The reagent for mitigating DARZALEX® (daratumumab) interference on Sebia IF gels
It is well known that the newer treatments for multiple myeloma that use humanized monoclonal antibodies (mAbs) can interfere with the patient’s native antibodies in immunofixation tests. This can mislead the pathologist in interpreting the patient’s response to treatment. Immunofixation is one of the tests referenced in the IMWG (International Myeloma Working Group) guidelines to establish the diagnosis of complete response in a patient with multiple myeloma.
HYDRASHIFT 2/4 daratumumab kits are to be used in conjunction with the HYDRAGEL IF kit and the semi-automated HYDRASYS 2 electrophoresis instrument. The procedure is a direct analysis without the need for sample pre-treatment.
See our range of Sebia Products here
Click here for Product details
